Some of the highlights for CXM:
CXM is currently trading at $0.57 and their 52 week high is $3.10
CXM announced submission of Urocool (TM) pelvic cooling catheter with FDA for 510(K) Clearance during their annual meeting in June 2009.
Cardium Announced Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds in current quarter of 2009.
Cardium Therapeutics (CXM:) turned to profit in Q3 2009. CXM reported third quarter net income of $4.9 million or $0.10 per share, compared to a net loss of $6.2 million or $0.13 per share in the previous year quarter.
No comments:
Post a Comment